Journal
JOURNAL OF CONTROLLED RELEASE
Volume 162, Issue 2, Pages 438-445Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2012.06.037
Keywords
Oral delivery; siRNA; Oligonucleotide; Clinical trial; Drug delivery
Funding
- National Science Foundation [CBET-1033746]
- National Science Foundation Graduate Research Fellowship Program [DGE-1110007]
- Directorate For Engineering
- Div Of Chem, Bioeng, Env, & Transp Sys [1033746] Funding Source: National Science Foundation
Ask authors/readers for more resources
The promise of short RNA or DNA segments such as siRNAs, antisense oligonucleotides, and transcription factor decoys to treat disease has prompted nearly 40 clinical trials for RNA interference (RNAi)-based therapeutics and more than 100 clinical trials for antisense oligonucleotide-based technologies; in fact, there are promising in vivo and preclinical studies for many hundreds of technologies. Current treatment strategies are largely injection-based, so effective oral delivery platforms for oligonucleotides may result in improved patient comfort and compliance. We analyze recently developed oral delivery methods for short RNA and DNA segments. (C) 2012 Elsevier B. V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available